Iron Homeostasis Throughout the Female Lifespan

Abstract

Iron homeostasis is a critical aspect of female health that evolves throughout a woman's life, influenced by physiological changes, hormonal fluctuations, and diverse clinical contexts. This review provides a comprehensive evaluation of iron metabolism from menarche through menopause and beyond, emphasizing the epidemiology, pathophysiological mechanisms, risk factors, clinical manifestations, diagnostic strategies, therapeutic interventions, and emerging advances. Special focus is given to guideline-based recommendations and clinically relevant insights for optimizing iron status in women at various life stages.

Introduction

The regulation of iron metabolism represents a cornerstone of women's health, impacting hematologic, neurologic, and reproductive outcomes. Female iron requirements and risks for deficiency or overload shift markedly from adolescence, through reproductive years, pregnancy, perimenopause, and into older age. Understanding these dynamic changes, underpinned by recent research and clinical guidelines, is essential for healthcare professionals managing iron status in female patients.

Epidemiology / Disease Burden

Globally, iron deficiency remains the most prevalent nutritional deficiency, disproportionately affecting women due to menstruation, pregnancy, and lactation. According to WHO estimates, over 30% of non-pregnant women of reproductive age are anemic, with iron deficiency accounting for the majority of cases. The burden is especially high during adolescence, in low-resource settings, and in women with heavy menstrual bleeding or multiple pregnancies. Conversely, iron overload disorders, though less common, also pose risks, particularly post-menopause when menstrual iron losses cease.

Pathophysiology

Iron homeostasis is tightly regulated through absorption, recycling, and storage processes. Hepcidin, a liver-derived peptide hormone, is the principal regulator, modulating intestinal iron absorption and macrophage iron release. During menarche and reproductive years, cyclic blood loss increases iron requirements, while pregnancy induces expansion of maternal blood volume and fetal iron transfer. Menopause marks a transition to reduced iron loss, shifting the balance toward potential iron accumulation. Disruptions in hepcidin regulation, genetic mutations (e.g., HFE gene), chronic inflammation, and comorbidities can further perturb iron metabolism at any life stage.

Risk Factors

Key risk factors for iron deficiency in females include excessive menstrual bleeding, vegetarian or vegan diets, gastrointestinal malabsorption (e.g., celiac disease, bariatric surgery), frequent blood donation, high parity, and low socioeconomic status. Obesity and chronic inflammatory conditions may also contribute to functional iron deficiency via elevated hepcidin. Conversely, hereditary hemochromatosis and reduced menstrual losses post-menopause increase the risk of iron overload.

Clinical Features

Iron deficiency symptoms are often nonspecific and may include fatigue, pallor, cognitive impairment, restless legs syndrome, and reduced exercise tolerance. In pregnancy, iron deficiency anemia is linked to adverse maternal and fetal outcomes, such as preterm delivery and impaired neurodevelopment. Iron overload may present with arthralgias, liver dysfunction, skin hyperpigmentation, and increased risk of diabetes or cardiomyopathy, particularly in genetically predisposed individuals.

Diagnosis

Accurate diagnosis of iron status relies on a combination of laboratory parameters. Serum ferritin is the most specific marker of iron stores but may be elevated in inflammation. Transferrin saturation (TSAT), serum iron, and total iron-binding capacity (TIBC) provide additional insights. In pregnancy, trimester-specific reference ranges are essential. Functional iron deficiency should be differentiated from absolute deficiency, particularly in chronic disease states. Genetic testing is reserved for cases of suspected hereditary hemochromatosis or unexplained iron overload.

Treatment & Management

Therapeutic strategies are tailored to the underlying etiology and life stage. Oral iron supplementation remains first-line for most cases of deficiency, with consideration of intravenous therapy in cases of intolerance, malabsorption, or severe anemia, especially during pregnancy. Dietary counseling is important to enhance iron intake and absorption. For iron overload, phlebotomy is the mainstay in hereditary hemochromatosis, with chelation reserved for specific indications. Regular monitoring of iron indices is critical to guide therapy and prevent complications.

Recent Advances / Emerging Therapies

Recent developments include novel oral iron formulations with improved bioavailability and tolerability, hepcidin antagonists for anemia of chronic disease, and non-invasive imaging (e.g., MRI) for quantifying tissue iron overload. Research on the interplay between iron metabolism and the gut microbiome, and the impact of hormonal contraceptives on iron status, is ongoing. Updated clinical practice guidelines have refined thresholds for diagnosis and treatment, emphasizing individualized care.

Guideline Recommendations

Major organizations, including WHO, CDC, and ACOG, recommend routine screening for iron deficiency in high-risk female populations, particularly during pregnancy and adolescence. Iron supplementation is advised for women with confirmed deficiency or increased requirements. Management protocols call for re-evaluation after 2-3 months of therapy, with escalation to intravenous iron for refractory cases. Postmenopausal women should be evaluated for iron overload if ferritin is elevated, with genetic counseling as appropriate. Guidelines underscore the importance of a life-course approach to iron management in females.

Conclusion

Iron homeostasis in women is a dynamic and complex process, shaped by physiological, genetic, and environmental factors across the lifespan. Clinicians must maintain vigilance for both iron deficiency and overload, leveraging evidence-based diagnostic and therapeutic strategies tailored to each patient's context. Ongoing research and emerging therapies hold promise for optimizing iron status and improving health outcomes for women worldwide.